Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 3,510,252 $ 1,902,832
General and administrative 1,460,419 2,035,686
Total operating expenses 4,970,671 3,938,518
Loss from operations (4,970,671) (3,938,518)
Other income (expense):    
Change in fair value of financial instruments (41,665) 1,980,672
Interest expense on convertible debt   (147,773)
Other income 52,905 10,774
Total other income (expense), net 11,240 1,843,673
Net loss (4,959,431) (2,094,845)
Other comprehensive loss    
Foreign currency translation adjustment (4,354) 47,841
Comprehensive loss $ (4,963,785) $ (2,047,004)
Net loss per share, basic $ (0.58) $ (0.29)
Net loss per share, diluted $ (0.58) $ (0.29)
Weighted-average shares outstanding of common shares, basic 8,579,284 7,195,529
Weighted-average shares outstanding of common shares, diluted 8,579,284 7,195,529